Inapsine and Malignant neoplasm progression - a phase IV clinical study of FDA data

Summary:

Malignant neoplasm progression is reported as a side effect among people who take Inapsine (droperidol), especially for people who are female, 60+ old, also take Dilaudid, and have High blood pressure.

The phase IV clinical study analyzes which people have Malignant neoplasm progression when taking Inapsine. It is created by eHealthMe based on reports of 259 people who have side effects when taking Inapsine from the FDA, and is updated regularly.

What is Inapsine?

Inapsine has active ingredients of droperidol. eHealthMe is studying from 260 Inapsine users. Check the latest studies of Inapsine.

What is Malignant neoplasm progression?

Malignant neoplasm progression (cancer tumour came back) is found to be associated with 1,508 drugs and 1,636 conditions by eHealthMe. Check the latest studies of Malignant neoplasm progression.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

259 people reported to have side effects when taking Inapsine.
Among them, 11 people (4.25%) have Malignant neoplasm progression.

Could Inapsine cause Malignant neoplasm progression?

Among these 11 people:

What is the gender of people who have Malignant neoplasm progression when taking Inapsine? *

female: 81.82 %
male: 18.18 %

What is the age of people who have Malignant neoplasm progression when taking Inapsine? *

What are other drugs people take besides Inapsine? *

What are other side effects people have besides Malignant neoplasm progression? *

Hypokalemia (low potassium): 9 people, 81.82%
High Blood Pressure: 8 people, 72.73%
Atelectasis (partial or complete collapse of the lung): 8 people, 72.73%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 8 people, 72.73%
Metastases To Bone (cancer spreads to bone): 8 people, 72.73%
Constipation: 8 people, 72.73%
Pain: 8 people, 72.73%
Pleural Effusion (water on the lungs): 8 people, 72.73%
Insomnia (sleeplessness): 8 people, 72.73%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 8 people, 72.73%

What are the existing conditions these people have? *

Pain: 2 people, 18.18%
High Blood Pressure: 2 people, 18.18%
Stress And Anxiety: 1 person, 9.09%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 9.09%
Prostate Cancer Metastatic: 1 person, 9.09%
Osteoporosis (bones weak and more likely to break): 1 person, 9.09%
Malignant Melanoma (skin cancer rises from melancytes): 1 person, 9.09%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 1 person, 9.09%
Breast Cancer Metastatic: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Inapsine and have Malignant neoplasm progression?

- Check whether Malignant neoplasm progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Inapsine:

Inapsine (260 reports)

Browse all side effects of Inapsine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Malignant neoplasm progression:

Malignant neoplasm progression (1,508 drugs)

Browse all the conditions that are associated with Malignant neoplasm progression:

Malignant neoplasm progression (1,636 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on droperidol (the active ingredients of Inapsine) and Inapsine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.